This Review is an overview of the unique characteristics of cyclodextrin in forming an inclusion complex via host–guest noncovalent interactions. The modification of cyclodextrin advances its application as a pharmaceutical solubilizer, fabrication of functional molecular machines such as polyrotaxane, polypseudorotaxane, and polycatenanes and grafting of cyclodextrin with different linear, branched chain polymers. The different stimuli‐based supramolecular assemblies involving cyclodextrin as a key mediator with linked triggering responses on payload release is highlighted. In addition, the applications of cyclodextrin in diagnostic imaging and medical devices is briefly demonstrated. Cyclodextrin is a relatively low cost, biocompatible, biodegradable, and highly explored material with low toxicity for drug formulation, drug delivery, and wide varieties of other biomedical applications such as those in medical devices fabrication, biosensor, tissue engineering, and bio‐imaging. The toxicological profile of cyclodextrin is well established and safe for human consumption in food and medicine.

Hyaluronan (HA) is a naturally occurring non-sulfated glycosaminoglycan (GAG), cell-surface-associated biopolymer and is the key component of tissue extracellular matrix (ECM). Along with remarkable physicochemical properties, HA also has multifaceted biological effects that include but not limited to ECM organization, immunomodulation, and various cellular processes. Environmental cues such as tissue injury, infection or cancer change downstream signaling functionalities of HA. Unlike native HA, the fragments of HA have diversified effects on inflammation, cancer, fibrosis, angiogenesis and autoimmune response. In this review, we aim to discuss HA as a therapeutic delivery system development process, source, biophysical-chemical properties, and associated biological pathways (especially via cell surface receptors) of native and fragmented HA. We also tried to address an overview of the potential role of HA (native HA vs fragments) in the modulation of inflammation, immune response and various cancer targeting delivery applications. This review will also highlight the HA based therapeutic systems, medical devices and future perspectives of various biomedical applications were discussed in detail.

Delivering drugs directly to the inflamed intestinal sites to treat inflammatory bowel disease (IBD), particularly Crohn's and ulcerative colitis, is highly challenging. Recent advances in colitis therapy medications are expanding opportunities for improving local on-site drug availability by minimising the associated systemic side-effects. Drug delivery with targeted carrier systems has shown the potential to increase site-specificity, stability, and therapeutic efficacy. Herein, we report the development of a strong anionic charged inflammation targeted nanocarriers (IT-NCs) loaded with an immunosuppressant model drug. This system showed preferential adhesion on a charge-modified surface in vitro, and in both dextran sulfate sodium (DSS) and TNBS colitis mice in vivo models. IT-NCs showed improved colitis phenotype therapeutic efficacy in both animal models compared to free drug. Furthermore, ex vivo study of colon tissue biopsies from patients with colitis revealed that IT-NCs adhered preferentially to inflamed biopsies compared to normal. Together, our results suggest that IT-NCs have promising therapeutic potential as delivery carriers' in colitis management.